Source-grounded facts extracted from BIO-RAD LABORATORIES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIO-RAD LABORATORIES, INC. reported first quarter ended March 31, 2026 results: revenue $592.1 million, net income $(527.1) million, EPS $(19.55) per diluted share.
“Financial Results Highlights GAAP Results Q1 2026 Q1 2025 Net sales (millions) $ 592.1 $ 585.4 Gross margin 52.3 % 52.3 % Income from operations (millions) $ 34.1 $ 23.7 Net income (loss) (millions) $ (527.1) $ 64.0 Income (loss) per diluted share $ (19.55) $ 2.29”
BIO-RAD LABORATORIES, INC. announced a restructuring with charges of between approximately $45 million and $50 million affecting operations in the United States (approximately 5% of our workforce).
“On February 7, 2025, Bio-Rad Laboratories, Inc. (the “Company”) initiated a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in the United States and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain operations to lower cost locations. The restructuring plan is expected to eliminate a total of approximately 5% of our workforce. We anticipate the restructuring plan will be substantially completed by the end of fiscal year 2025. We estimate that as a result of this restructuring plan we will incur between approximately $45 million and $50 million in total cost, which we anticipate will consist primarily of one-time termination benefits to the affected employees, including cash severance payments, healthcare benefits, and related transition assistance.”
Norman Schwartz changed role as President at BIO-RAD LABORATORIES, INC..
“Effective on Mr. DiVincenzo’s September 9, 2024 start date as the Company’s President and Chief Operating Officer, Norman Schwartz will continue as the Company’s Chief Executive Officer and Chairman of the Board and will no longer be the Company’s President.”
Andrew Last departed as Executive Vice President, Chief Operating Officer at BIO-RAD LABORATORIES, INC..
“Dr. Last will be retiring from his position on September 5, 2024.”
Jonathan P. DiVincenzo was appointed as President and Chief Operating Officer at BIO-RAD LABORATORIES, INC..
“On August 20, 2024, Bio-Rad Laboratories, Inc. (the “Company”) announced the appointment by the Board of Directors of the Company of Jonathan P. DiVincenzo as the Company’s President and Chief Operating Officer (including as principal operating officer), effective September 9, 2024.”
BIO-RAD LABORATORIES, INC. reported the first quarter ended March 31, 2024 results: revenue $610.8 million, net income $383.9 million, EPS $13.45 per share, on a diluted basis.
“Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023. On a currency-neutral basis, quarterly sales decreased 9.6 percent compared to the same period in 2023. Life Science segment net sales for the first quarter were $241.7 million, a decrease of 25.3 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 25.2 percent compared to the same quarter in 2023. The currency-neutral year-over-year sales decrease was broad-based and was primarily driven by ongoing weakness in the biotech and biopharma end-markets and the economic environment in China. Clinical Diagnostics segment net sales for the first quarter were $368.6 million, an increase”
BIO-RAD LABORATORIES, INC. shareholders approved Approval of the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended at the 2024-04-23 meeting.
“3. The proposal to approve the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:”
BIO-RAD LABORATORIES, INC. shareholders approved Ratification of KPMG LLP as independent auditors at the 2024-04-23 meeting.
“2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2024 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:”
BIO-RAD LABORATORIES, INC. shareholders approved Election of Directors at the 2024-04-23 meeting.
“1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows:”
Roop K. Lakkaraju was appointed as Executive Vice President and Chief Financial Officer (and principal financial officer) at BIO-RAD LABORATORIES, INC..
“On April 26, 2024, the Company disclosed that Roop K. Lakkaraju, the Company’s Executive Vice President and Chief Financial Officer (and principal financial officer) will act as the Company’s principal accounting officer.”
James J. Barry was appointed as Executive Vice President and President, Life Science Group at BIO-RAD LABORATORIES, INC..
“On April 24, 2024, James J. Barry, currently the Company’s Senior Vice President of Global Manufacturing, was appointed to the position of Executive Vice President and President, Life Science Group, effective May 1, 2024.”
Simon May resigned as Executive Vice President and President, Life Science Group at BIO-RAD LABORATORIES, INC..
“On April 22, 2024, Simon May, the Executive Vice President and President, Life Science Group, of Bio-Rad Laboratories, Inc. (the “Company”) and a named executive officer of the Company, notified the Company of his plans to resign from the Company to pursue another opportunity, effective as of May 1, 2024.”
Andrew Last departed as Executive Vice President, Chief Operating Officer at BIO-RAD LABORATORIES, INC..
“On April 10, 2024, Dr. Andrew Last, the Executive Vice President, Chief Operating Officer (and principal operating officer) of Bio-Rad Laboratories, Inc. (the “Company”), notified the Company that he intends to retire from his position by early September 2024.”
Roop K. Lakkaraju was appointed as Executive Vice President, Chief Financial Officer at BIO-RAD LABORATORIES, INC..
“On March 20, 2024, Bio-Rad Laboratories, Inc. (the “Company”) announced the appointment by the Board of Directors of the Company of Roop K. Lakkaraju as the Company’s Executive Vice President, Chief Financial Officer (including as principal financial officer), effective April 15, 2024.”
BIO-RAD LABORATORIES, INC. reported the quarter ended December 31, 2023 results: revenue $681.2 million, net income $349.7 million, EPS $12.14 per share, on a diluted basis.
“Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth-quarter 2023 total net sales were $681.2 million, a decrease of 6.7 percent compared to $730.3 million reported for the fourth quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.7 percent compared to the same period in 2022. COVID-related sales were approximately $0.3 million in the fourth quarter of 2023 versus approximately $13.4 million in the year ago period. Excluding COVID-related sales, revenue decreased 6.0 percent on a currency-neutral basis. Life Science segment net sales for the fourth quarter were $291.1 million, a decline of 19.1 percent compared to the same period in 2022. On a currency-neutral basis, Life Science segment sales decreased by 19.9 percent compared to the same quarter in 2022. Excluding COVID-related sales, Lif”
BIO-RAD LABORATORIES, INC. incurred revolving credit of $200,000,000 with Wells Fargo Bank, National Association, as agent at Term SOFR plus 0.10% per annum plus the Applicable Margin maturing February 13, 2029.
“all commitments thereunder. No penalties were due in connection with such repayments. Borrowings under the Revolving Credit Agreement are permitted up to a maximum amount of $200,000,000 on a revolving basis, including up to $25,000,000 of letters of credit. Borrowings of revolving loans may be made, at the Borrowers’ election, in U.S. dollars, Euros, Swiss”
BIO-RAD LABORATORIES, INC. terminated Previous Revolving Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., HSBC Bank USA, National Association, and MUFG Bank, Ltd. as co-syndication agents, and Citibank, N.A. and Wells Fargo Bank, National Association as co-documentation agents (effective 2024-02-14).
“The Company repaid in full all outstanding obligations under the Previous Revolving Credit Agreement on February 14, 2024 and terminated all commitments thereunder.”
BIO-RAD LABORATORIES, INC. entered into Revolving Credit Agreement with Wells Fargo Bank, National Association, as agent valued at $200,000,000 (effective 2024-02-13).
“Bio-Rad Laboratories, Inc. (the “Company”) entered into a Credit Agreement dated as of February 13, 2024 (the “Revolving Credit Agreement”), by and among the Company, Bio-Rad Europe GmbH, Bio-Rad IHC Europe GmbH and Bio-Rad Laboratories (Singapore) Pte Ltd (collectively, the “Borrowers”), the lenders referred to therein, and Wells Fargo Bank, National Association, as agent.”
Norman Schwartz was appointed as principal financial officer at BIO-RAD LABORATORIES, INC..
“On February 9, 2024, the Company’s board of directors appointed Norman Schwartz, the Company’s President and Chief Executive Officer and the Chairman of the Board, as the Company’s principal financial officer until a permanent replacement for Mr. Daskal has been appointed.”
Ilan Daskal resigned as Executive Vice-President, Chief Financial Officer at BIO-RAD LABORATORIES, INC..
“Ilan Daskal resigned from his position as the Company’s Executive Vice-President, Chief Financial Officer and the Company’s principal financial officer in order to pursue other opportunities.”
Dara Grantham Wright departed as Executive Vice-President and President, Clinical Diagnostics Group at BIO-RAD LABORATORIES, INC..
“On December 4, 2023, Dara Grantham Wright, the Executive Vice-President and President, Clinical Diagnostics Group, of Bio-Rad Laboratories, Inc. (the “Company”) and a named executive officer of the Company, notified the Company of her plans to resign from the Company to pursue another opportunity, effective at the close of business on January 12, 2024.”
BIO-RAD LABORATORIES, INC. reported the third quarter ended September 30, 2023 results: revenue $632.1 million, net income $106.3 million, EPS $3.64 per share. Guidance lowered.
“life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2023. Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.9 percent compared to the”
Ilan Daskal resigned as Executive Vice-President, Chief Financial Officer at BIO-RAD LABORATORIES, INC..
“On October 12, 2023, Ilan Daskal, the Executive Vice-President, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”) and the Company’s principal financial officer, notified the Company of his plans to resign from the Company to pursue another opportunity, effective at the close of business on November 6, 2023.”
Tania DeVilliers was appointed as interim principal accounting officer at BIO-RAD LABORATORIES, INC..
“Upon effectiveness of Mr. Ramalingam’s resignation and until a permanent successor is appointed by the Company, Tania DeVilliers will act as the Company’s interim principal accounting officer, in addition to her current position as Senior Director, Corporate Controller.”
Ajit Ramalingam departed as Senior Vice-President, Chief Accounting Officer at BIO-RAD LABORATORIES, INC..
“On August 21, 2023, Ajit Ramalingam, the Senior Vice-President, Chief Accounting Officer of Bio-Rad Laboratories, Inc. (the “Company”) and the Company’s principal accounting officer, notified the Company of his plans to resign from the Company, effective at the close of business on September 18, 2023.”
BIO-RAD LABORATORIES, INC. reported the second quarter ended June 30, 2023 results: revenue $681.1 million, net income $1,162.3 million, EPS $39.59 per share. Guidance reaffirmed.
“Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $691.1 million reported for the second quarter of 2022.”
BIO-RAD LABORATORIES, INC. reported the first quarter ended March 31, 2023 results: revenue $676.8 million, net income $69 million, EPS $2.32 per diluted share.
“First-quarter 2023 net sales were $676.8 million, a decrease of 3.3 percent compared to $700.1 million reported for the first quarter of 2022.”
BIO-RAD LABORATORIES, INC. shareholders rejected Stockholder proposal regarding political disclosure at the 2023-04-25 meeting.
“5. The stockholder proposal regarding political disclosure was not approved since the proposal did not receive the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes Votes Votes Broker For Against Abstaining Non-Votes 1,100,154 5,935,081 17,489 225,785”
BIO-RAD LABORATORIES, INC. shareholders approved Non-binding advisory vote on the frequency of future advisory votes to approve executive compensation at the 2023-04-25 meeting.
“4 With respect to the non-binding advisory vote on the frequency of future advisory votes to approve executive compensation, Three Years received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes Votes Votes Votes Broker 1 Year 2 Years 3 Years Abstaining Non-Votes 1,575,550 14,432 5,461,754 989 225,785”
BIO-RAD LABORATORIES, INC. shareholders approved Non-binding advisory vote to approve executive compensation at the 2023-04-25 meeting.
“3. The non-binding advisory vote to approve executive compensation was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes Votes Votes Broker For Against Abstaining Non-Votes 6,772,070 277,497 3,158 225,785”
BIO-RAD LABORATORIES, INC. shareholders approved Ratification of selection of KPMG LLP as independent auditors at the 2023-04-25 meeting.
“2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes Votes Votes Broker For Against Abstaining Non-Votes 7,258,298 19,666 547 -”
BIO-RAD LABORATORIES, INC. shareholders approved Election of Directors at the 2023-04-25 meeting.
“1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows: Class of Common Stock Votes Votes Votes Broker to Elect For Against Abstaining Non-Votes Melinda Litherland Class A 14,950,990 5,818,104 4,785 1,695,304 Arnold A. Pinkston Class A 15,729,846 5,037,217 6,816 1,695,304 Jeffrey L. Edwards Class B 4,974,972 275 90 56,255 Gregory K. Hinckley Class B 4,974,972 275 90 56,255 Allison Schwartz Class B 4,972,669 2,578 90 56,255 Norman Schwartz Class B 4,972,669 2,578 90 56,255”
BIO-RAD LABORATORIES, INC. reported the full year ended December 31, 2022 results: revenue $2,802.2 million.
“On a reported basis, net sales for the full year 2022 decreased 4.1 percent to $2,802.2 million compared to $2,922.5 million for the prior year.”
BIO-RAD LABORATORIES, INC. reported Fourth-quarter 2022 results: revenue $730.3 million, net income $827.7 million, EPS $27.78 per share, on a diluted basis.
“Fourth-quarter 2022 net sales were $730.3 million, a decrease of 0.3 percent compared to $732.8 million reported for the fourth quarter of 2021.”
BIO-RAD LABORATORIES, INC. reported financial results for the fourth quarter and full year ended December 31, 2022.
“Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022.”
BIO-RAD LABORATORIES, INC. reported the third quarter ended September 30, 2022 results: revenue $680.8 million, net income $164.2 million, or a loss of $5.52 per share, on a diluted basis.
“in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022. Third-quarter 2022 net sales were $680.8 million, a decrease of 8.9 percent compared to $747.0 million reported for the third quarter of 2021. COVID-related revenue was approximately $17 million in the third quarter of 2022”
Alice N. Schwartz was appointed as Director Emeritus at BIO-RAD LABORATORIES, INC..
“On March 23, 2022, the Company’s Board of Directors appointed Mrs. Schwartz as a Director Emeritus, effective as of April 26, 2022.”
Alice N. Schwartz departed as Director at BIO-RAD LABORATORIES, INC..
“On March 23, 2022, Alice N. Schwartz, a director and co-founder of Bio-Rad Laboratories, Inc. (the “Company”), informed the Company of her decision not to stand for re-election to the Company’s Board of Directors at the 2022 Annual Meeting of Stockholders.”
Annette Tumolo departed as Executive Vice President, President, Life Science Group at BIO-RAD LABORATORIES, INC..
“On September 28, 2021, Annette Tumolo, the Executive Vice President, President, Life Science Group, of Bio-Rad Laboratories, Inc. (the “Company”) and a named executive officer of the Company, informed the Company of her intention to retire from her position at the Company, effective January 4, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.